Article | October 25, 2017

Achieving Optimal mAb Titer and Quality Through Cell Culture Media and Supplement Optimization

Source: Catalent

James W. Brooks, Emily Gramiccioni, Thomas O’Brien, and Nuvjeevan S. Dosanjh

Achieving Optimal mAb Titer

Considered the cornerstone of modern therapeutics, mAbs has the innate ability to bind target proteins and initiate immune responses such as antibody-dependent cellular cytotoxicity (ADCC), making them highly effective therapeutic agents. However, their therapeutic efficacy is heavily dependent on appropriate quality characteristics.  In the bioproduction process, appropriate mAb quality can take multiple forms, including correct sequence, proper glycosylation, and limited protein aggregation and charge heterogeneity.